再生元制药公司 REGN 深 沪
交易中 01-28 11:01:59 美东时间
754.39
-16.860
-2.19%
华盛通- 最 高766.985
- 今 开765.15
- 成交量 10.87万股
- 最 低 752.40
- 昨 收 771.25
- 总市值 814.74亿
- 52周最高 821.11
- 市盈率 静 19.68
- 换手率 0.10%
- 52周最低 474.7269
- 委 比 -1.54%
- 总股本 1.08亿
- 历史最高 1207.6799
- 量 比 0.72
- 振 幅 1.89%
- 历史最低 39.31
- 每 手 1
- 风险率 82.16%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多BUZZ-Intellia jumps as FDA lifts hold on gene‑editing trial for rare nerve disease
BUZZ-Intellia jumps as FDA lifts hold on gene‑editing trial for rare nerve disease ** Shares of gene therapy developer Intellia Therapeutics NTLA.O rise 21% to $16.87 premarket ** Co says U.S. FDA has lifted clinical hold on its late‑stage trial testing nex‑z for hereditary ATTR amyloidosis with pol
01-27 21:20
美股大行评级 | 潜在涨幅258.31%！Tempest Therapeutics获HC Wainwright上调评级至"买入"，目标价11美元
今日重点评级关注：HC Wainwright & Co.：上调Tempest Therapeutics评级至"买入"，目标价11美元；Guggenheim：维持Sportradar Gr"买入"评级，目标价从34美元升至35美元
01-23 19:46
Evercore ISI Group Maintains Outperform on Regeneron Pharmaceuticals, Raises Price Target to $875
Evercore ISI Group analyst Cory Kasimov maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Outperform and raises the price target from $750 to $875.
01-22 23:34
Ocular Therapeutix™ Appoints David W. Robinson as Global Chief Commercial Officer
Ocular Therapeutix appoints David W. Robinson as Global Chief Commercial Officer to lead the launch of AXPAXLI for wet AMD and NPDR. Robinson, with extensive experience in retina drug launches, including EYLEA at Regeneron and global ophthalmology marketing at Merck, brings strategic expertise to advance AXPAXLI's global potential. His leadership will support the company's commercial readiness and expansion in retinal therapies, building on his s...
01-21 12:00
Regeneron Advances Early-Stage Eye Drug Pozelimab in Geographic Atrophy Trial
Regeneron Pharmaceuticals ($REGN) announced an update on their ongoing clinical...
01-16 00:34
JPM 2026：AI破局，肥胖引爆，巨头血战新王座
作者：贝壳社 2026年，转型与产出的关键之年。 作为全球生物医药行业的“风向标”，在2026年JMP大会上，礼来、默沙东、罗氏、诺华、赛诺菲、武田、再生元、百...
01-15 17:11
Kiniksa Pharmaceuticals Provides Corporate Update
Kiniksa Pharmaceuticals reported ARCALYST net product revenue of $677.5 million in 2025, up 62% from 2024. 2026 revenue is expected to reach $900-$920 million. KPL-387 Phase 2 data is anticipated in H2 2026, while KPL-1161 Phase 1 trials aim to begin by year-end. Cash balance rose to $414.1 million in 2025, supporting ongoing efforts and future opportunities.
01-12 12:30
美股大行评级 | 潜在涨幅197.4%！奥麦罗制药获HC Wainwright升目标价至40美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持奥麦罗制药"买入"评级，目标价从20美元升至40美元；HC Wainwright & Co.：维持Cullinan Therapeutics"买入"评级，目标价从26美元升至27美元
01-09 20:22
Truist Securities Maintains Buy on Regeneron Pharmaceuticals, Raises Price Target to $820
Truist Securities analyst Gregory Renza maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Buy and raises the price target from $798 to $820.
01-09 01:23
